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Abstract
Background—In order to prevent the spread of the hepatitis C virus (HCV) amongst Hispanic
injecting drug users (IDUs), we developed, validated, and implemented a multimedia educational
intervention program.
Methods—A pre-post intervention study design was used to evaluate long-lasting knowledge and
behavior changes in a group of 88 poor Hispanic HIV-infected IDUs. Pre-intervention data was
compared with data measured six months after the intervention.
Results—A significant increase in the awareness regarding HCV clinical manifestations, HCV
risky behaviors, HCV prevention practices and HIV/HCV co-infection synergisms was observed
in the group six months post intervention.
Conclusion—Our study confirms the long-lasting benefits of multimedia based intervention
programs for disseminating HCV prevention strategies in IDUs. Therefore, preventive educational
approaches that use images, figures, and animations tools can be recommended to target and tailor
interventions for vulnerable populations.
Introduction
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are blood-borne
pathogens, commonly transmitted by sharing drug injecting equipment and paraphernalia
used in the preparation and administration of drugs for injection.1-3 Both viral infections are
unevenly distributed across ethnic groups of injecting drug users (IDUs) in the US and
elsewhere, with US African Americans and Hispanics having disproportionately higher
rates.3-5 Although significant advances have been made in preventing HCV and HIV-
infection in IDUs, there are still gaps which must be addressed.1, 6 Syringe exchange
programs (SEP) and methadone maintenance treatment programs (MMTP) are well known
prevention strategies designed to engage the individual in harm reduction practices for HCV
and HIV transmission.7-9 However, additional prevention strategies are needed, especially in
countries where these type of programs are poorly designed or implemented. In Puerto Rico
for example, less than 15% of the syringes used by IDUs come from SEP. Most are from
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private sellers who do not necessarily provide educational information on how to reduce
risks of blood borne infections.10 Consequently, complementing SEP and MMTP
approaches with prevention strategies that promote safe injection education is critical.11-13
Based on this need, we developed and implemented a multimedia HCV prevention
intervention program for vulnerable persons, based on the Health Belief Model (HBM) and
Social Cognitive Theory (SCT) framework.14 The principal behavioral target of this
intervention was the reduction of HCV-associated risk behaviors among Hispanic HIV-
infected IDUs. Previously published results described the feasibility, acceptability, and
immediate short-term effectiveness of this program.14, 15 The present study is reporting the
long lasting knowledge and behavior’s changes, measured six months after the intervention.
Methods
Study design
The study was an intervention trial conducted on a group of HIV-infected persons recruited
from February 2006 through December 2008. Participants were HIV-infected IDUs visiting
the Retrovirus Research Center (RRC) in Bayamón, Puerto Rico, for HIV-related care. Most
of the patients seen through the RRC have an annual family income below the US Federal
Poverty Level. A test-retest study design was used to evaluate the effects of a novel
multimedia educational intervention based on the HBM and SCT framework.14-15 A self-
administered questionnaire evaluated changes in HCV knowledge, perception of disease
severity and infection’s susceptibility, as well as changes in HCV risk behavior practices in
HIV-infected persons. The questionnaire was administered at eight weeks and six months
after the intervention. The instrument utilized Likert scales, with other measures, to evaluate
disease severity perceptions and risk behavior practices. This study’s educational
intervention description, study design, study implementation, instrument description,
outcome measures collection and evaluation have been described in previously published
work.14-15 The study was conducted with the approval of the Institutional Review Board
(IRB) of the Universidad Central del Caribe, at Bayamón Puerto Rico.
Statistical analysis
Differences in the data within baseline and between baseline and follow-up were assessed
with Chi Square, t-test, McNemar and Wilcoxon signed ranks tests. Non- parametric tests
were used to avoid unequal pairwise correlation across repeated measures and to correct for
small sample size effects. A 2-tailed p-value of less than 0.05 was used to evaluate statistical
significance. Statistical analyses were performed using Statistical Package of Social
Sciences (SPSS Inc., Chicago, IL).
Results
Study enrollment
Of the total of 138 participants enrolled in the study, 88 (63.7%) completed the 6-month
evaluation questionnaire. No statistical differences at enrollment were observed between
those who completed and those who did not completed this evaluation (Table 1). Of the 88
participants, 72 (81.8%) were male and 72 (81.8%) were co-infected with HCV (Table 1).
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The mean age was 42.7years, with a standard deviation (SD) of ± 9.2 years and the mean
educational level was 10th grade. All the study participants had an annual family income that
was below the US Federal Poverty Level. Over one third of them (39.8%) reported active
drug injection practices during the six months prior to study enrollment; 20 (22.7%)
reporting active drug injection practices during the previous month before enrollment into
the study (table 1).
Hepatitis and HCV knowledge changes
Six months from baseline, study participants showed a significant improvement in their
ability to accurately define hepatitis as liver damage and to identify the presence of a virus
as the cause of the HCV (Table 2). Similarly, knowledge concerning viral distribution in
bodily fluids, HCV clinical manifestations, HCV treatments, and HCV co-infection
increased significantly at the 6th month’s re-evaluation (Table 2). This knowledge
improvement was more relevant in relation to the HCV treatment, lack of HCV vaccine, and
HIV co-infection (Table 2). Knowledge of HCV-infection associated risk behaviors also had
an incremental increase over time, especially in relationship to sharing drug paraphernalia,
sharing razors, unprotected sex, and getting body piercings (Table 3). Conversely, the
significant reduction in the misconceptions that coughing, sneezing, or sharing food/utensils
contributed to the HCV transmission remained in the 6th month’s re-evaluation (Table 3).
HCV perception of severity
The perception of HCV infection as a severe healthcare disease remained high over the
study period. However, the perception of HCV infection as a cause for liver cirrhosis and
cancer slightly decreased over the study period (Table 4). The current intervention
highlighted the positive effect of an adequate and opportune HCV therapy in the infection’s
prognosis, and the spontaneous remission in over 20% of the cases. Based on these data, we
can hypothesize that the HCV knowledge improvement could be related to this awareness’s
reduction.
HCV risk-behavior changes
The number persons who reported active drug injecting behaviors in the previous month
decreased from 20 at enrollment to 12 at the six month evaluation. Similarly, the reported
HCV risk behavior, related to their injecting drug use practices, decreased significantly
compared to baseline, especially in the use of shooting galleries and in paraphernalia sharing
(Table 4).
Discussion
It is well known that drug users, especially IDUs are one of the most vulnerable groups to
increased risk of infection and reduced access to healthcare, health education, and
prevention strategies.3, 16 Existing limitations in access to HCV and HIV education and
preventive interventions in IDUs increases the transmission of the viruses.8 Because HCV
and HIV are easily spread through the blood, especially during drug injection process, it is
generally accepted that the strategies to prevent HCV transmission among IDUs will also
prevent HIV transmission.1, 8, 16 Syringe exchange programs, a well-known prevention
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strategy for preventing blood-borne infections, exist in Puerto Rico; however, they are not
commonly used by IDUs. Syringes are obtained primarily from private sellers, who do not
typically provide educational strategies that emphasis the reduction of the HCV
transmission.10
The present study supported that the HCV multimedia educational intervention created for
IDUs could produce durable health-related behavior changes by improving the HCV
infection knowledge and by promoting preventive strategies. Our previous publication
reported knowledge improvement and HCV risk behaviors reduction two months after the
intervention. The present study demonstrated that these changes were sustained six months
post-intervention.
Given the high HCV prevalence in the participant group, the more relevant prevention issue
for this study is if there would be a reduction of further HCV transmission, rather than a
reduced incidence of HCV infection in the participants. The high baseline prevalence of
HCV in the study group has limited the possibility of evaluating the prevention effects of the
multimedia intervention in reducing the HCV incidence among uninfected IDUs. This
represents a study limitation that requires further evaluation. However, there was a sustained
reduction in the sharing of syringes and drug preparation equipment reported by the
participants. This behavior change would directly reduce the opportunities for cross-
contamination of these devices with HCV infected blood. In theory, a reduction in the
infection source would have a preventive effect among the uninfected population.
Interrupting HCV and HIV transmission has been seen as the optimal goal and standard
public health concept of disease reduction.17 Lessening the HCV burden from the risky
behavior practices would reduce the scope of the virus transmission, diminishing the overall
incidence of HCV in IDUs.
This study does have several limitations. First, not all participants completed the 6th month
post-intervention evaluation, introducing a potential source of bias. Second, the study
measured only self-reported behaviors which may have been an under- or overestimation of
the actual behavior change. Third, participants’ tendency to provide socially acceptable or
desired responses to the questionnaire may have introduced bias into the data. Fourth, a low
prevalence of active injecting drug use in the study group may limit the program’s goal of
reducing HCV-infection risk behavior. Therefore, this multimedia intervention would need
to be implemented in uninfected IDUs at an earlier stage of drug addiction and with a higher
level of active drug use in order to confirm the lasting preventive trend suggested here.
In conclusion, this computer-based intervention appears to be helpful in generating durable
changes related to HCV knowledge improvements and reducing HCV risk behavior among
Hispanic HIV-infected IDUs. The introduction of similar preventive strategies in this
frequently inaccessible and marginalized population may ultimately serve to decrease this
hard-to-control healthcare issue.
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Table 1
Baseline findings by groups of persons who completed and did not completed the 6th month post intervention
evaluation
Completed (n=88) Not completed (n=50) P-value
Male (%) 81.8 86.0 0.274
Age at study entry (mean± SD) 42.7±9.2 40.4±9.1 0.149
Educational level (mean± SD) 10±3.2 10±2.9 0.653
Age of first IDU (mean± SD) 20.2±18.9 20.4±19.1 0.880
IDU in the last month (%) 22.7 36.0 0.093
IDU in the last semester (%) 39.8 50.0 0.244
HCV co-infected at enrolment (%) 81.8 82.6 0.768
HCV knowledge (%)
 HCV is predominantly in blood 90.9 97.9 0.104
 Not all HCV-infected patients have symptoms 54.5 60.0 0.534
 HCV infection can lead to liver cancer 74.1 70.0 0.524
 HCV treatment is available 58.1 70.0 0.160
 An HCV vaccine is not available 36.8 44.0 0.377
 Not all HCV treated persons get cured 72.9 66.0 0.406
 HCV treatment could affect HIV therapy 33.7 30.0 0.951
 Not all HIV/HCV persons can receive HCV therapy 23.0 30.0 0.345
HCV risk behavior knowledge (%)
 Used of injecting drugs 98.7 94.0 0.291
 Reusing cookers or filters from other IDUs 84.1 78.0 0.507
 Sharing paraphernalia for cocaine sniffing 59.1 60.0 0.807
 Coughing and sneezing 35.2 26.0 0.296
 Sharing eating utensils 46.6 38.0 0.377
 Having unprotected sex 79.5 46.0 0.784
 Men having sex with men (n=113) 66.2 54.8 0.226
HCV prevention self confidence (median (IQR))
 Using their own syringe 10 (9-10) 10 (10-10) 0.378
 Not using others’ filters or cottons 10 (6-10) 10 (8.8-10) 0.269
 Utilizing water from their own containers 10 (9-10) 10 (9.8-10) 0.677
 Not permitting others to use their water containers 10 (8.3-10) 10 (10-10) 0.436
 Refusing to let their syringes be back loaded 10 (7-10) 10 (8.8-10) 0.712
 Rejecting used filters or cookers 10 (8-10) 10 (6.8-10) 0.905
HCV = Hepatitis C; IDU=Injecting drug use; IDUs=Injecting drug user; SD=Standard deviation; IQR= Inter Quartile Rate
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Table 2
Pre- and post-intervention knowledge evaluation
Liver, Hepatitis, and HCV virus knowledge Day 0 (%) 8th Week (%) 6th Month (%)
Hepatitis means liver damage or harm 87.5 97.7* 97.7*
The liver has a metabolic function 64.8 66.7 67.0
HCV is a viral condition 75.0 84.9 86.4
HCV is predominantly in the blood 90.9 95.4 97.7
HCV is not predominantly in urine 71.6 83.9 89.8*
HCV is not predominantly in stools 75.0 81.6 85.2
HCV is not predominantly in semen 62.5 70.2 69.3
Not all HCV-infected patients have symptoms 54.7 61.6 60.2
Over 50% of HCV-infected develop chronic infection 83.0 74.7 87.5
HCV infection can lead to liver cancer (n=87) 74.7 70.6 75.9
HCV treatment is available (n=87) 58.6 72.1* 70.1
An HCV vaccine is not available (n=87) 35.6 52.9* 59.8*
Not all HCV treated persons get cured (n=86) 72.1 75.3 74.4
HCV treatment could affect HIV therapy(n=87) 34.5 52.9* 69.0*
Not all HIV/HCV persons can receive HCV therapy 22.7 37.9* 33.0
*
p value < 0.05 between baseline and second or third evaluations, by McNemar’s Test
HCV = Hepatitis C; HIV= Human Immunodeficiency virus






















Mayor et al. Page 9
Table 3
Pre- and post-intervention HCV risk-behavior knowledge evaluation
Risk behaviors Day 0 (%) 8th Week (%) 6th Month (%)
Reusing syringe during drug injection 98.9 97.7 98.9
Reusing cookers or filters from other IDUs 84.1 92.0 95.4*
Getting a tattoo under unhygienic conditions 93.2 91.9 90.9
Performing unhygienic body piercing 86.4 88.5 89.8
Sharing paraphernalia for cocaine sniffing 59.1 86.2* 85.2*
Sharing razors with others 84.1 83.9 85.2
Coughing and sneezing 35.2 12.6* 10.4*
Food preparation 12.5 6.8 10.2
Sharing eating utensils 46.6 20.9* 22.7*
Having unprotected sex 79.5 82.4 81.8
*
p value < 0.05 between baseline and second evaluations, by McNemar’s Test
Test HCV = Hepatitis C; IDUs= injecting drug user
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Table 4
Pre- and post-intervention HCV severity perception and HCV risk behavior evaluation
HCV-infection issues Day 0 Median(IQR) 8th Week Median(IQR) 6th Month Median(IQR)
HCV severity perception
HCV infection is a severe disease 10.0 (7.0-10) 10.0 (8.0-10) * 10.0 (8.0-10)
HCV infection can cause death 7.0 (5.0-10) 6.0 (5.0-10) 6.0 (4.0-8.8)
HCV infection can cause liver cirrhosis 9.0 (6.0-10) 8.0 (6.0-10) 8.0 (5.0-10)*
HIV/HCV infection can cause death 10.0 (6.0-10) 8.0 (5.0-10) 8.0 (5.0-10)*
HCV infection can cause liver cancer 8.0 (5.0-10) 7.0 (5.0-10) 7.0 (5.0-9.0)
Injecting drug use risk behaviors in the previous 30 days (n =
20)
Using a shooting gallery to inject drug 8.0 (0-10) 0 (0-8.0)* 0 (0-7.8)*
Utilizing water previously used by another IDUs 1.0 (0-8.8) 0 (0-4.0)* 0 (0-0)*
Utilizing cooker previously used by another IDUs 2.0 (0-9.0) 0 (0-6.25)* 0 (0-0)*
Utilizing filter or cotton previously used by IDUs 0 (0-6.8) 0 (0-2.75) 0 (0-0)
Collecting drug from a cooker after another IDUs 0 (0-7.2) 0 (0-2.0)* 0 (0-0)
Back loading syringes 0.5 (0-6.5) 0 (0-1.0) 0 (0-0)
Utilizing another IDUs’s syringe 1.0 (0-5.3) 0 (0-0) 0 (0-0)
Score scale from 0 (none) - 10 (very high or very frequent)
*
p value < 0.05 between baseline and the second or third evaluations, by Wilcoxon Test
HCV = Hepatitis C; IQR=Inter Quartile Rate; IDUs=Injecting drug user
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